File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

TitleUse of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
Authors
Keywordschemoradiotherapy
clinical trial eligibility
consolidation therapy
real-world population
treatment utilization
Issue Date10-Jan-2023
PublisherWiley Open Access
Citation
Thoracic Cancer, 2023, v. 14, n. 6, p. 563-572 How to Cite?
Abstract

Background

Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non-small-cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for durvalumab in routine clinical practice.

Methods

We evaluated eligibility for durvalumab in a real-world clinical setting and the impact of eligibility on outcomes. Consecutive patients treated with concurrent chemoradiotherapy at two tertiary centers between January 2015 and June 2022 were assessed. Clinical characteristics and outcomes were evaluated based on eligibility criteria for the PACIFIC trial.

Results

A total of 126 patients were included. Seventy patients (56%) were eligible for durvalumab. Ineligibility was associated with shorter progression-free survival of 9.7 months versus 18.4 months (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.39–0.95, p = 0.029) and overall survival of 26.4 months versus 58.7 months (HR 0.47, 95% CI 0.28–0.80, p = 0.005). Common reasons for ineligibility were history of previous malignancy (32%) and progressive disease or death during chemoradiotherapy (25%). Ineligible patients who received durvalumab had similar outcomes to eligible patients who received durvalumab.

Conclusions

In a real-world cohort, adjuvant durvalumab is safe and beneficial in a substantial proportion of patients who would not have been eligible for the PACIFIC trial.


Persistent Identifierhttp://hdl.handle.net/10722/340991
ISSN
2023 Impact Factor: 2.3
2023 SCImago Journal Rankings: 0.778
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBoys, Emma-
dc.contributor.authorGao, Bo-
dc.contributor.authorHui, Rina-
dc.contributor.authorda Silva, Inês-
dc.contributor.authorHau, Eric-
dc.contributor.authorGee, Harriet-
dc.contributor.authorNagrial, Adnan-
dc.date.accessioned2024-03-11T10:48:51Z-
dc.date.available2024-03-11T10:48:51Z-
dc.date.issued2023-01-10-
dc.identifier.citationThoracic Cancer, 2023, v. 14, n. 6, p. 563-572-
dc.identifier.issn1759-7706-
dc.identifier.urihttp://hdl.handle.net/10722/340991-
dc.description.abstract<h3>Background</h3><p>Durvalumab following concurrent chemoradiotherapy is standard treatment for unresectable stage III non-small-cell lung cancer based on the results of the PACIFIC trial. Based on trial criteria, not all patients are eligible for durvalumab in routine clinical practice.</p><h3>Methods</h3><p>We evaluated eligibility for durvalumab in a real-world clinical setting and the impact of eligibility on outcomes. Consecutive patients treated with concurrent chemoradiotherapy at two tertiary centers between January 2015 and June 2022 were assessed. Clinical characteristics and outcomes were evaluated based on eligibility criteria for the PACIFIC trial.</p><h3>Results</h3><p>A total of 126 patients were included. Seventy patients (56%) were eligible for durvalumab. Ineligibility was associated with shorter progression-free survival of 9.7 months versus 18.4 months (hazard ratio [HR] 0.61, 95% confidence interval [CI] 0.39–0.95, <em>p</em> = 0.029) and overall survival of 26.4 months versus 58.7 months (HR 0.47, 95% CI 0.28–0.80<em>, p</em> = 0.005). Common reasons for ineligibility were history of previous malignancy (32%) and progressive disease or death during chemoradiotherapy (25%). Ineligible patients who received durvalumab had similar outcomes to eligible patients who received durvalumab.</p><h3>Conclusions</h3><p>In a real-world cohort, adjuvant durvalumab is safe and beneficial in a substantial proportion of patients who would not have been eligible for the PACIFIC trial.</p>-
dc.languageeng-
dc.publisherWiley Open Access-
dc.relation.ispartofThoracic Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectchemoradiotherapy-
dc.subjectclinical trial eligibility-
dc.subjectconsolidation therapy-
dc.subjectreal-world population-
dc.subjecttreatment utilization-
dc.titleUse of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study-
dc.typeArticle-
dc.identifier.doi10.1111/1759-7714.14780-
dc.identifier.scopuseid_2-s2.0-85146186202-
dc.identifier.volume14-
dc.identifier.issue6-
dc.identifier.spage563-
dc.identifier.epage572-
dc.identifier.eissn1759-7714-
dc.identifier.isiWOS:000911628700001-
dc.identifier.issnl1759-7706-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats